Benitec gets FDA Fast Track for BB-301 in OPMD; 100% response rate in Cohort 1

Benitec Biopharma Inc.

FDA granted Fast Track Designation to BB-301 for OPMD with dysphagia; BB-301 also has Orphan Drug Designation from FDA and EMA.
All six Cohort 1 patients met statistical response criteria (100% response rate) with significant improvements in dysphagia measures.
First Cohort 2 patient treated in Q4 2025; Benitec plans FDA meeting in 2026 to confirm pivotal study design.
Appointed Dr. Sharon Mates to board; she was co-founder/CEO of Intra-Cellular Therapies (acquired by JNJ for ~$14.6B in 2025).

item 5.02 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-261665
form_type: 8-K
ticker: BNTC
cik: 0001808898
company_name: Benitec Biopharma Inc.
filed_at: 2025-11-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.536446+00:00
generated_at: 2026-05-17T00:55:49.044718+00:00
sec_items: ["5.02", "7.01", "8.01", "9.01"]
event_type: regulatory
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-261665
json_url: https://secwatch.observer/filing/0001193125-25-261665.json
markdown_url: https://secwatch.observer/filing/0001193125-25-261665.md
text_url: https://secwatch.observer/filing/0001193125-25-261665.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312525261665/0001193125-25-261665-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312525261665/bntc-20251102.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

RGTI

Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity

Rigetti Computing, Inc. May 21, 2026, 7:30 AM ET regulatory Items 3.02, 8.01, 7.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

REPL

Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review

Replimune Group, Inc. May 29, 2026, 9:56 AM ET regulatory Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

GROO

Groovy dismisses auditor after SEC suspension, reduces authorized common 99.5%, two officers depart

GROOVY COMPANY, INC. May 28, 2026, 3:28 PM ET regulatory Items 4.01, 4.02, 5.03, 5.02, 9.01

same SEC item: 5.02, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

BBIO

FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026

BridgeBio Pharma, Inc. May 27, 2026, 4:01 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

VSTD

Vestand receives Nasdaq delisting notice for late quarterly and annual filings

Vestand Inc. May 26, 2026, 5:18 PM ET regulatory Items 3.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-261665

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.